September 2, 2026: Park Medi World is entering a phase where the size of its expansion pipeline could become as important as its existing hospital network.
Author: Aadarsh Patel | EQMint
A recent Ventura Securities report estimates that the company has visibility for 2,680 additional beds across acquisitions, greenfield projects, brownfield expansions and a public-private partnership in Uttar Pradesh. The report maintains a BUY rating and raises its target price to ₹406 from ₹284 earlier, implying 41.9% upside from the market price of ₹286 cited in the report.
The interesting part is the way Park is adding capacity. The company is combining owned hospitals with acquisitions, expansions of existing facilities and asset-light operating models.
2,680 Beds in the Pipeline
Park Medi World’s project pipeline includes hospitals and expansions across North India.
The list includes a 350-bed greenfield hospital in Panchkula, a 200-bed acquisition in Narela, a 330-bed hospital in Rudrapur, a 400-bed hospital in Gorakhpur, a 150-bed Mohali expansion, a 200-bed Ambala expansion, a 250-bed Rohtak hospital, a 100-bed Palam Vihar expansion, a 150-bed Zirakpur acquisition and a 550-bed PPP hospital in Prayagraj. Together, these projects add up to 2,680 beds.
This gives Park a fairly visible route for capacity growth over the next few years.
The project mix also matters. Brownfield expansion allows the company to add beds around existing infrastructure, while acquisitions can bring operating hospitals into the network faster.
Prayagraj PPP Changes the Capital Equation
The proposed 550-bed Prayagraj hospital is one of the more interesting pieces of the pipeline.
Under a 45-year concession, Park Medi World plans to develop and operate a multi-speciality hospital with estimated capex of around ₹200 crore. Of this, ₹76.52 crore, or roughly 38%, is expected to be reimbursable.
The project also involves an annual concession fee of ₹18.10 crore, with a 3% annual escalation.
For Park, the appeal is capital efficiency. The company can expand into Uttar Pradesh while reducing the upfront capital burden compared with a conventional greenfield project.
The Prayagraj project also connects with Park’s existing presence in Agra and planned presence in Gorakhpur, creating a wider Uttar Pradesh cluster.
Park’s Low-Capex Model Is Central to the Story
Park Medi World’s expansion strategy becomes more interesting when viewed through its cost per bed.
The Ventura report puts Park’s capex per bed at around ₹37 lakh, while the FY27-FY28 expansion programme is budgeted at a blended ₹36 lakh per bed. Acquisitions have been even more capital efficient at around ₹34 lakh per bed.
The planned 100-bed Palam Vihar expansion is expected to require only around ₹25 lakh per bed.
The company also commissioned its 360-bed Agra facility within 2 months of acquisition, according to the report.
This combination of acquisitions, brownfield expansion and cluster-based operations is helping Park add capacity without relying entirely on expensive greenfield development.
Occupancy Could Become the Next Earnings Driver
Adding beds creates capacity. Filling those beds creates revenue.
Park’s existing hospitals provide some evidence of the operating model. Hospitals operating above 60% occupancy generate EBITDA margins of around 30-31%, compared with 15-20% for hospitals below 60% occupancy, according to the Ventura report.
New units are already EBITDA-positive from the first year at around 10-12%.
Mohali provides an example of the potential ramp-up. Its EBITDA margin moved from 12-13% in the first year to 18-19% in the second year and around 26% currently, with EBITDA of approximately ₹23 crore.
Rudrapur is expected to follow a similar trajectory, with revenue projected to rise from ₹100 crore in its first year to ₹140 crore in the second year, while EBITDA could increase from ₹20-22 crore to ₹35-36 crore.
ARPOB Is Moving Higher Too
Another part of the earnings story is average revenue per occupied bed, or ARPOB.
Park’s blended ARPOB increased from ₹26,206 to ₹30,040, helped by a richer case mix and a 440-basis-point increase in super-speciality revenue share to 61.7%.
The report still describes Park’s positioning as affordable and volume-led.
Around 77% of patients are covered under government schemes, giving the company a large patient base while leaving room for ARPOB improvement as the specialty mix becomes richer.
That’s an important part of the thesis. Park can potentially grow through both more beds and higher revenue generated from each occupied bed.
Financial Growth Expectations Are Strong
Ventura Securities expects Park Medi World to deliver revenue, EBITDA and PAT CAGRs of 26.8%, 28.8% and 33.4% respectively between FY26 and FY29E.
The estimates put FY29 revenue at ₹3,420 crore, EBITDA at ₹949 crore and PAT at ₹631 crore. EBITDA margin is expected to rise from 26.4% to 27.8%, while PAT margin could improve from 15.7% to 18.5%.
The research firm attributes the expected improvement to capacity additions, higher ARPOB, ramp-up of newer hospitals, better specialty and payer mix, operating leverage and lower finance costs.
Uttar Pradesh Could Become a Bigger Growth Market
The Uttar Pradesh strategy deserves separate attention.
The state has significantly lower hospital-bed density compared with western and southern India, according to the Ventura report. Park is building its presence through Agra, the planned Gorakhpur hospital and the Prayagraj PPP.
That gives the company access to markets where organised healthcare supply remains relatively limited.
The PPP model could become especially useful if Park can replicate it in other locations, although the report notes that no additional PPP projects have been formally announced so far.
The Rerating Case Comes Down to Execution
The research report’s valuation call is based on a stronger earnings outlook and the company’s expansion pipeline.
Ventura Securities has revised its target price to ₹406, compared with its earlier target of ₹284, while maintaining its BUY rating.
The company still has risks to manage. The report points to slower consumer premiumisation and inflationary pressures as risks to the upside.
And there is a simpler operational question: can Park commission thousands of new beds and fill them without putting pressure on returns?
EQMint Take
Park Medi World’s story is increasingly about capital efficiency meeting capacity expansion.
The company has a 2,680-bed project pipeline, is entering new markets such as Uttar Pradesh, and is using acquisitions and brownfield expansion alongside conventional greenfield development.
The rerating argument rests on Park converting that pipeline into occupied beds, higher ARPOB and stronger margins.
The beds are coming. The numbers will depend on how quickly the patients follow.
For more such information visit EQMint
Join our Whatsapp channel for timely updates: Whatsapp
Disclaimer: This article is not an investment advice and is for educational purpose only.
